REDWOOD CITY, Calif., Aug. 07, 2024 (GLOBE NEWSWIRE) -- Revolution Medicines, Inc. (NASDAQ:RVMD), a clinical-stage oncology company developing targeted therapies for patients with RASaddicted cancers, today announced its financial results for the quarter ended June 30, 2024, and provided an update on corporate progress. The company continues making progress on its 2024 development priorities: Advancing its RAS(ON) multi-selective inhibitor RMC-6236 into monotherapy pivotal trials. Pancreatic cancer: The com ...